Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Randomized Prospective Study
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Twenty-six symptomatic subjects with clinical evidence plus either high-resolution computed tomography (HRCT, n = 25) or open-lung biopsy (OLB, n = 1) patterns typical for idiopathic usual interstitial pneumonia (idiopathic UIP) were entered into a randomized prospective treatment trial using high-dose prednisone (n = 12) versus colchicine (n = 14). The minimum dose of prednisone used was 60 mg/d for 1 mo, tapered to 40 mg/d over the second month, tapered to 40 mg every other day during the third month, with subsequent doses adjusted as clinically indicated. The dose of colchicine was 0.6–1.2 mg/d, as tolerated. The presence of a rim of subpleural honeycomb change was present in all of the 25 subjects who had HRCT. Subjects treated with high-dose prednisone alone experienced a higher incidence of serious side effects and also exhibited a trend (not statistically significant, p = 0.391) to more rapid decline of pulmonary function and shortened survival than did those treated with colchicine alone. In most subjects with typical clinical and HRCT features of idiopathic UIP, neither prednisone nor colchicine resulted in objective improvement, and the disease continued to progress in the majority. Colchicine appears to be a safer alternative to a trial of high-dose prednisone but may be no different than no therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other immune-modulators and chemotherapeutic agents such as azathioprine, imatinib, and etanercept have not been shown to be effective in IPF patients [51,56–59].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [58]
Citations
Cites
Lung Function Testing: Selection of Reference Values and Interpretative Strategies
(1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.5.1202 · Cited by 2,510
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 3×
“Mortality rates were similar for subjects in this study diagnosed using mostly clinical and HRCT criteria without OLB compared with an historical group of idiopathic UIP subjects diagnosed by OLB ( 6 ) without HRCT (Figure 2). This finding supports our contention that rigorous clinical and HRCT criteria can serve as a…”
MethodResultSelf-citationThe epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
Natural History and Treated Course of Usual and Desquamative Interstitial Pneumonia
Carrington, C. B., Gaensler, E. A., Coutu, R. E., FitzGerald, M. X., & Gupta, R. G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804132981501 · Cited by 791
Nonspecific Interstitial Pneumonia/Fibrosis: Histologic Features and Clinical Significance
Katzenstein, A.-L. A., & Fiorelli, R. F. (1994) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199402000-00003 · Cited by 755
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival
Turner-Warwick, M., Burrows, B., & Johnson, A. (1980) · Thorax · doi:10.1136/thx.35.3.171 · Cited by 508
Raghu, G., Depaso, W. J., Cain, K., Hammar, S. P., Wetzel, C. E., Dreis, D. F., Hutchinson, J., Pardee, N. E., & Winterbauer, R. H. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.291 · Cited by 414
Remy-Jardin, M., Giraud, F., Remy, J., Copin, M. C., Gosselin, B., & Duhamel, A. (1993) · Radiology · doi:10.1148/radiology.189.3.8234692 · Cited by 364
Johnson, M. A., Kwan, S., Snell, N. J., Nunn, A. J., Darbyshire, J. H., & Turner-Warwick, M. (1989) · Thorax · doi:10.1136/thx.44.4.280 · Cited by 289
Research works printed but not linked: 5
- Hampton, 1994, Corticosteroids in idiopathic pulmonary fibrosis (IPF): toxicity may outweigh benefits (abstract)., Am. Rev. Respir. Dis, 149, A878
- Miller, 1983, Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state., Am. Rev. Respir. Dis, 127, 270
- Miller, 1986, Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations from a probability sample of Michigan, a large industrial state., Bull. Eur. Physiopathol. Respir, 22, 589
- Midthun, 1998, Nonspecific interstitial pneumonia: clinical, radiographic, and pathologic features (abstract)., Am. J. Respir. Crit. Care Med, 157, A277
- Raghu, 1995, Interstitial lung disease: a diagnostic approach., Am. J. Respir. Crit. Care Med, 151, 909, 10.1164/ajrccm/151.3_pt_1.909 · doi:10.1164/ajrccm/151.3_pt_1.909
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Metadata
- Authors
- DOUGLAS, W. W., RYU, J. H., SWENSEN, S. J., OFFORD, K. P., SCHROEDER, D. R., CARON, G. M., & DeREMEE, R. A.
- Affiliations
- Mayo Clinic (US)
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-07-01
- Volume
- 158
- Issue
- 1
- Pages
- 220-225
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1862182724
- Cited by
- 182
- References
- 25
- Citations by year
- 2024: 4 · 2023: 1 · 2022: 6 · 2021: 5 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 4 · 2014: 8 · 2013: 9 · 2012: 4
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, colchicine, prednisone, corticosteroid therapy, high-dose prednisone, adverse drug reactions, lung function decline, survival, disease progression
- MeSH terms
- Aged, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Colchicine, Female, Humans, Male, Middle Aged, Prednisone, Prospective Studies, Pulmonary Fibrosis, Respiratory Function Tests, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Randomized Prospective Study. https://app.cochat.ai/papers/10.1164/ajrccm.158.1.9709089
- The paper
- DOUGLAS, W. W., RYU, J. H., SWENSEN, S. J., OFFORD, K. P., SCHROEDER, D. R., CARON, G. M., & DeREMEE, R. A. (1998). Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Randomized Prospective Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.158.1.9709089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.